Tevogen Bio Holdings Inc. (TVGN)

Tevogen Bio Holdings, Inc. (TVGN) stock has experienced significant volatility. The stock reached its all-time high of $21.09 on February 14, 2024, and its all-time low of $0.2556 on October 8, 2024. Over the last year, the stock has shown a -77.86% decrease. As of October 24, 2025, the stock closed at $0.67. Key events impacting the stock include the company changing its name in February 2024, announcing plans to expand the target population for TVGN 489 in May 2025, and announcing updates in September 2025, including a major milestone in its AI initiative, highlighting the potential role of TVGN 489 in eliminating persistent viral reservoirs linked to Long COVID, and estimating a 5-year top-line revenue of approximately $6.5 billion for a product focused on liver cancer prevention with high-risk chronic Hepatitis B infection. In October 2024, Tevogen Bio planned to update shareholders on multi-billion dollar asset valuation following a $1 billion+ revenue potential announcement and provided timelines associated with recently announced revenue forecasts and updates on operational readiness.

There is no explicit information available regarding demand seasonality for Tevogen Bio Holdings, Inc.'s products and services. Demand for its products, once commercialized, would likely be driven by disease prevalence, treatment efficacy, regulatory approvals, and market adoption rather than typical seasonal consumer patterns. For infectious diseases, there could be an indirect link to seasonal outbreaks, but this is not specifically mentioned in the provided information.

Tevogen Bio Holdings, Inc. is a clinical-stage specialty immunotherapy company focused on developing off-the-shelf precision T cell therapies for infectious diseases, cancers, and neurological disorders. The company operates within the Health Technology sector, specifically in the Biotechnology industry, focusing on Biological Products (No Diagnostic Substances). Tevogen Bio's core technology is its proprietary ExacTcell platform, designed to create accessible and disease-specific cellular immunotherapies. Its major product candidates include TVGN 489, which has completed Phase 1 clinical trials for COVID-19 patients and is in Phase 1 clinical trials for acute SARS-CoV-2 patients with B-cell cancer immune suppression, other B cell immune-suppressed acute SARS-CoV-2 patients with a B-cell cancer indication, and for Long COVID prevention and treatment, TVGN 920, TVGN 960, TVGN 601, TVGN 930 and TVGN 116 which are in preclinical trials for treating cervical cancer, oropharyngeal cancer, multiple sclerosis, Epstein-Barr virus associated lymphomas and hepatitis B, respectively. The company also leverages artificial intelligence (AI) initiatives to accelerate drug discovery, enhance the efficacy of T cell-based therapies, and expedite clinical trial participation.

Tevogen Bio Holdings, Inc. is headquartered in Warren, New Jersey, United States. The company has an international intellectual property presence, with Patent Cooperation Treaty (PCT) applications covering virus-specific T-cells and methods of treating and preventing viral infections entering the national stage in the US, Australia, Canada, Europe, Hong Kong, and Japan. Additionally, patent applications for its AI approach have entered the national stage in the US, Australia, Canada, Europe, Japan, Qatar, Saudi Arabia, and the United Arab Emirates. Specific details on commercial operations or market reach beyond its headquarters and intellectual property filings are not extensively disclosed.

Tevogen Bio Holdings, Inc. has actively communicated its advancements and strategic initiatives, contributing to its brand reputation. The company has emphasized its commitment to AI, launching Tevogen.AI and the PredicTcell model to accelerate drug discovery and enhance T-cell therapies. Tevogen has highlighted the potential of its TVGN 489 product in addressing Long COVID, including its role in eliminating persistent viral reservoirs and its potential impact for millions of Americans. The company has released valuations of its key assets, such as TVGN 489, and provided revenue forecasts for pipeline products, aiming to close the information gap for shareholders. Tevogen has expressed gratitude for Yale's recognition of its CEO, Dr. Ryan Saadi, and the company's mission of health equity.

Tevogen Bio Holdings, Inc. exhibits a highly concentrated ownership structure. Institutional ownership is notably low, estimated at around 1.3% to 1.4%, primarily consisting of index funds. In contrast, insider ownership is significantly high, ranging from 74% to 79%, largely attributed to the founder, Dr. Ryan Saadi, and other early insiders. This indicates strong alignment on paper between insiders and the company's success, but also means a tiny public float, which can lead to higher stock price volatility.